Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.
FDA Clears IND Application for CID-103 in Immune Thrombocytopenia
Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations
Age, Genetics Help Predict Proliferative Sickle Cell Retinopathy
Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
Febuxostat Use Is Linked to Reduced Risk of Kidney Events for Patients with Gout
HCV Tops HBV as Leading Cause of Cirrhosis, Global Burden Projected to Increase